NBI-921352
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for NBI-921352, covering 2024-09-26 to 2025-10-16. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) [Phase 2]